Titan Biotech Q2 FY27 Results: Net Profit ₹12.5 Cr, Up 60.3% YoY
Titan Biotech Ltd reported revenue from operations of ₹76.5 Cr (+40.6% YoY) and net profit of ₹12.5 Cr (+60.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.5 Cr · +60.3% YoY
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Titan Biotech Ltd reported revenue from operations of ₹76.5 Cr (+40.6% YoY) and net profit of ₹12.5 Cr (+60.3% YoY) for Q2 FY27.
Titan Biotech's board meets 05 November 2026 to consider unaudited quarterly and half-year results. Trading window stays closed until 48 hours after outcome declaration.
Titan Biotech allotted 1,03,29,625 bonus shares of Rs. 2 each in a 1:4 ratio. Paid-up capital rose to Rs. 10.33 Crore post-allotment.
Titan Biotech Limited has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Titan Biotech Ltd fixed October 23, 2026, as the record date for its 1:4 bonus share issue. Allotment is scheduled for October 26, 2026.
Titan Biotech increased its authorised share capital from Rs. 10 Crore to Rs. 10.40 Crore, following shareholder approval at the 34th Annual General Meeting.
Titan Biotech Limited held its 34th Annual General Meeting on September 29, 2026. The meeting transacted ordinary and special business, including financial adoption and director appointments.